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MinireviewAutoreactive CD8 T Cells
in Organ-Specific Autoimmunity:
Emerging Targets for Therapeutic Intervention
diabetic patients transplanted with pancreas grafts from
healthy monozygotic co-twins or HLA-identical siblings
(reviewed in Vizler et al., 1999). Nonobese diabetic (NOD)
mice develop a disease, closely resembling human T1D,
that requires both CD4 and CD8 T cells. Since  cells
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do not express MHC class II molecules, it has been2 Department of Pathology and Microbiology
proposed that autoreactive CD4 T cells differentiate intoSchool of Medical Sciences
effectors by engaging  cell antigens (shed during theUniversity of Bristol
physiological remodeling of tissue or by a prior insult)Bristol BS8 1TD
on local antigen-presenting cells (APCs). Studies inUnited Kingdom
2-microglobulin-deficient NOD mice have suggested3 Department of Microbiology and Infectious Diseases
that the initial  cell insult might be effected by cytotoxicFaculty of Medicine
CD8 T cells, which are consistently recruited to islets inUniversity of Calgary
NOD mice (DiLorenzo et al., 1998; Amrani et al., 2000).Calgary, Alberta T2N 4N1
A CD8 T cell population that recognizes an insulin-Canada
derived peptide in islets of 3- to 4-week-old prediabetic
NOD mice has been reported (Wong et al., 1999). This
T cell population shrinks with age (Wong et al., 1999;The importance of CD8 T cells in the pathogenesis of
Amrani et al., 2000) and is replaced, in part, by anotherorgan-specific autoimmune diseases has not pre-
population of highly diabetogenic CD8 T cells that useviously been well recognized. Recent evidence, how-
homologous V17-J42 TCR chains (Verdaguer et al.,ever, indicates that autoreactive CD8 T cells can con-
1997; DiLorenzo et al., 1998). This V17-J42 populationtribute substantially to tissue damage in both murine
is already a significant component in the earliest NODand human autoimmune disorders. As such, these T
islet CD8 T cell infiltrate (DiLorenzo et al., 1998). Thecells now become an attractive target for therapeutic
natural self-peptide recognized by these diabetogenic Tintervention.
cells is unknown, but screening of combinatorial peptide
libraries led to the identification of a mimotope peptide,CD8 T cells play a major role in immune responses, their
designated NRP, which behaves as a full agonist (Ander-natural function being related to protection against viral
son et al., 1999). This population expands in size asinfections and tumors. They perform this function by
the mice age and undergoes an “avidity maturation”cytotoxic damage of target cells expressing MHC class
process that coincides with an accelerated phase ofI molecules and the relevant antigenic peptide as well
disease and contributes to the progression from benignas by the production of effector cytokines such as IFN.
insulitis to overt disease (Amrani et al., 2000). This phe-As almost all cells express MHC class I molecules, it is
nomenon indicates that interclonal competition has aclear that there is great potential for tissue damage. The
major influence on the progression of autoimmunity.importance of CD8 T cells in autoimmune diseases such
The mechanisms underlying the seemingly hierarchicalas type 1 diabetes (T1D), rheumatoid arthritis (RA), auto-
recruitment of CD8 T cells targeting different autoanti-immune thyroiditis, and multiple sclerosis (MS) had not
gens into pancreatic islets are unclear. However, the
previously been well recognized, perhaps in part be-
earlier recruitment of insulin- versus NRP-reactive CD8
cause genetic susceptibility and resistance to these dis-
T cells cannot be accounted for by differences in the
eases are profoundly affected by polymorphisms of MHC peripheral precursor frequency of the different subpop-
class II genes, with little evidence for an independent ulations (P.S., unpublished data). Differences in accessi-
role for the closely linked MHC class I genes. Technical bility to antigen crosspresentation pathways (see below)
difficulties in expanding and maintaining autoreactive or in the timing or levels of expression of different au-
CD8 T cells in vitro have also hindered their in-depth toantigens might play a role. It is also reasonable to
analysis. However, CD8 T cells are emerging as impor- suggest that competition for APC resources or other
tant contributors to tissue damage in murine and human antigen-independent factors contribute to the dynamics
autoimmune disorders. of T cell recruitment in organ-specific autoimmunity.
From these and other  cell antigen-specific CD8 T
Evidence for a Pathogenic Role cell clones, a number of TCR-transgenic NOD mice have
of Autoreactive CD8 T Cells been generated that develop diabetes. Interestingly, the
T1D is a prototypic organ-specific autoimmune disease development of diabetes in each of these lines is differ-
in which CD8 T cells play a critical role in pancreatic  ent, especially after crosses with RAG/ or SCID mice.
cell destruction. T1D in humans is associated with cer- One study has shown that the transgenic CD8 T cells
tain MHC class I alleles, and CD8 T cells are abundant may not require CD4 T cells to cause diabetes (Graser
among the mononuclear cells that infiltrate the pancre- et al., 2000), while another indicates that CD4 T cells may
atic islets (insulitis) at clinical onset of disease and in contribute to the recruitment to the islets (Verdaguer et
al., 1997). A third transgenic TCR appears to destine
thymocytes for developmental arrest or negative selec-4 Correspondence: susan.wong@bristol.ac.uk (F.S.W.), psantama@
ucalgary.ca (P.S.) tion, as mature CD8 T cells only develop when a suc-
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cessful endogenous rearrangement is present (Kana- cytotoxic granules being oriented toward the contact
gawa et al., 2000). zone. CD8 T cells of either autoreactive or as yet un-
A number of other transgenic models of T1D have known specificity have been implicated in a number
been generated in which mice expressing neo-autoanti- of other organ-specific autoimmune diseases both in
gens exclusively in  cells (expression driven by the animal models and humans (e.g., thyroiditis, vitiligo,
rat insulin promoter [RIP]) were mated with transgenic polymyositis, inflammatory bowel disease, primary bili-
mice expressing neo-autoantigen-specific, MHC class ary cirrhosis).
I-restricted TCRs (RIP-hemagglutinin [HA]  TCR, RIP-
lymphocytic choriomeningitis virus [LCMV] proteins  Activation of Autoreactive CD8 T Cells
TCR, and RIP-ovalbumin [OVA]  TCR models). In the The activation of naive CD8 T cells requires triggering
HA and OVA models, diabetes develops spontaneously by MHC:peptide and costimulatory molecules ex-
early on in life (Vizler et al., 1999). In contrast, in the pressed on the surface of a specialized APC, most likely
LCMV model the autoreactive CD8 T cells are ignorant, a dendritic cell (DC) (Figure 1). How, where, and when
and diabetes does not occur unless mice are infected CD8 T cells recognize MHC:self-peptide in spontaneous
with LCMV or crossed on a genetic background favoring autoimmune disorders is not well understood. Target
enhanced T cell responsiveness (Garza et al., 2002). cells usually cannot drive CD8 T cell responses in the
Collectively, these studies underline the pathogenic po- absence of professional APCs, as they express MHC
tential of autoreactive CD8 T cells but reveal some heter- class I molecules but not costimulatory molecules. One
ogeneity. These differences have not been formally means of CD8 T cell priming is crosspresentation of
compared but probably relate to the density of tissue-specific self-antigen by DCs (Heath and Carbone,
MHC:self-peptide complexes recognized, the affinity of 2001). This process has been demonstrated for soluble
the TCR for the MHC:peptide complex, and the genetic and cell-associated self-antigens. DCs can process cel-
backgrounds of the transgenic mice. lular antigens from apoptotic cells, and both apoptotic
MS is a chronic human disease caused by inflamma- and necrotic cells can promote immune responses by
tory cell-induced demyelination in the central nervous activating DCs. It has recently been shown that the effi-
system (CNS). Infiltrating CD8 T cells predominate over ciency of crosspriming increases with (1) high antigen
CD4 T cells, especially in regions of active demyelin- level in the target tissue, (2) induction of apoptosis in
ation, and these CD8 T cells appear to undergo local self-antigen-expressing cells, (3) presence of autoreac-
clonal expansion as assessed by analysis of TCR gene tive CD4 T cells, (4) presence of immune complex-form-
rearrangements at the single-cell level (Babbe et al., ing autoantibodies, and (5) high T cell precursor fre-
2000). Autoreactive CD8 T cells responsive to myelin- quency (Heath and Carbone, 2001; Kita et al., 2002).
derived peptides have been reported in MS patients that Whether spontaneous autoimmune CD8 T cell re-
have the potential to kill HLA class I-matched oligoden- sponses are skewed toward antigenic targets that can
drocytes in vitro, independent of exogenous peptide. access antigen crosspresentation pathways in special-
Experimental autoimmune encephalomyelitis (EAE) is an ized APCs such as CD8 DCs remains to be determined,
experimental model for MS, induced in susceptible ani-
but it is a possibility. Priming of NRP-reactive CD8 T
mals by immunization with myelin antigens. Although auto-
cells, for example, specifically occurs in the pancreatic
reactive CD4 T cells are implicated as major effectors
lymph nodes, and its magnitude increases with the de-
of EAE, there is evidence pointing to a role for CD8 T
gree of cell death (Zhang et al., 2002). Posttranslationalcells in disease progression and severity. For example,
modifications of intracellular proteins, such as thosea myelin oligodendrocyte glycoprotein-derived peptide
occurring during the process of apoptosis (i.e., phos-has recently been shown to elicit encephalitogenic CD8
phorylation or caspase cleavage), might create neo-anti-T cells in vivo (Sun et al., 2001). In addition, myelin basic
gens capable of bypassing tolerance and priming auto-protein (MBP) is processed and presented in vivo by
reactive CD8 T cell responses, as proposed for certainthe MHC class I pathway, and, in fact, responding CD8
autoantibody responses (Utz et al., 1997).T cell clones induce a CNS immunopathology in mice
In T1D models, the requirement for CD4 T cell help inthat resembles some forms of MS, implicating CD8
the activation of autoreactive CD8 T cells is not universalT cells as potential effectors of demyelination in MS
(Vizler et al., 1999, Graser et al., 2000; Garza et al., 2002),(Huseby et al., 2001).
although clearly needed in most cases. For instance,In addition, it is clear that CD8 T cells can also kill
naive NRP-reactive CD8 T cells undergo activation inneurons in vitro (Medana et al., 2000). This mechanism
the pancreatic lymph nodes by engaging autoantigenmight contribute to the axonal loss observed in MS and
on professional APCs but do not efficiently accumulateto the pathogenesis of several human autoimmune dis-
in islets in the absence of CD4 T cells (Verdaguer et al.,eases of low prevalence, such as paraneoplastic neuro-
1997). This suggests that initiation of T1D requires a logical syndromes and Rassmussen’s encephalitis (a
cell insult and the rapid recruitment of autoreactive CD8CNS inflammatory disease causing epilepsy). Indeed,
T cells, one or both steps being CD4 dependent. Theexpanded populations of HLA-A2-restricted, onconeu-
role of CD4 T cells in the activation of CD8 T cells isral antigen (cdr2)-specific CD8 T cells have been de-
probably not restricted to the induction of  cell damagetected in the blood of cancer patients presenting with
and likely involves the activation of APCs, possibly viaparaneoplastic cerebellar degeneration as a result of
ligation of CD40 by CD154 (Figure 1). CD40 engagementselective autoimmune destruction of Purkinje cells (Al-
endows APCs with the ability to costimulate CD8 T cellsbert et al., 1998). Furthermore, in Rassmussen’s enceph-
and to foster their differentiation. Indeed, stimuli thatalitis lesions, CD8 T cells are found in close contact with
2-microglobulin-expressing degenerating neurons, their activate DCs, such as agonistic anti-CD40 mAb or CpG
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Figure 1. Activation, Differentiation, and Recruitment of Autoreactive CD8 T Cells as Targets for Therapeutic Intervention in Organ-Specific
Autoimmunity
CD8 T cell-induced autoimmunity might be inhibited at the systemic level by depletion of APC types capable of crosspresenting target cell-
derived peptides, by depletion of antigen-activated T-helper cells (explosives), or by potentiating the suppressor activity of regulatory T cells
(ambulance). Strategies that might be effective at the regional level include costimulatory blockade, inhibition of CD8 T cells trafficking to the
target tissue or of antigen-loaded APCs to the regional lymphoid tissue, inhibition of death effector pathways, and inhibition of apoptotic cell
capture by local APCs (stop sign).
DNA, uncouple the need for CD4 T cell help in the activa- Effector Pathways in CD8 Autoimmunity
CTL can directly kill target cells through at least twotion and recruitment of NRP-reactive CD8 T cells in vivo
(Amrani et al., 2002). In the RIP-LCMV model, the activa- different pathways. The differential roles of Fas-Fas li-
gand- and perforin-induced  cell damage in diabetestion of low-avidity CD8 T cells by LCMV infection is
sufficient to induce diabetes. This may occur by activa- are controversial; their relative importance may be de-
pendent on the etiology. Studies in the LCMV model oftion of the local APCs, as CD80 expression in the pan-
creas could also prime for T1D. T1D suggested a major role for perforin in  cell death.
Using a similar model, Seewaldt et al. (2000) have arguedThe role of localized inflammation in diabetes has
been studied using a double transgenic model in which for a major role for cytokines as (direct or indirect) ef-
fectors of  cell death in virus-induced T1D. In contrast,RIP-CD80 is stably expressed in the islets, whereas local
expression of TNF can be rapidly repressed with tetra- studies of perforin- or Fas-deficient NOD mice have also
yielded apparently contradictory results: perforin-defi-cycline (Green and Flavell, 2000). On a C57BL/6 back-
ground, neither the presence of TNF nor CD80 alone cient NOD mice develop severe insulitis but rarely be-
come diabetic, and NOD.lpr mice develop neither diabe-gives rise to diabetes. When TNF is repressed in the
RIP-CD80 transgenic mice after postnatal day 30, a tes nor insulitis despite expressing perforin. It is likely
that in the NOD mouse both pathways are important butCD8-dependent diabetes occurs rapidly, and when it is
repressed at day 25, diabetes develops with delayed not necessarily involved to the same extent at all stages
of disease, with evidence suggesting that Fas-Fas ligandkinetics. However, if TNF is repressed at day 21, diabe-
tes is prevented. There is apparently a critical time win- interactions are important in the earlier phases and other
mechanisms of cell damage become progressively moredow in this model that determines whether autoreactive
CD8 T cells differentiate into fully diabetogenic effectors. important. In the NRP-specific TCR transgenic NOD
mice, autoreactive CD8 T cells kill  cells exclusively viaDuring this time window, highly potent CD4CD25 reg-
ulatory T cells accumulate in the pancreatic islets and Fas. The Fas-dependent lysis of  cells is significantly
enhanced by a number of cytokines, including IL-1, IL-lymph nodes if TNF is repressed at day 25 (Green et
al., 2002). If this process can be generalized, it would 1, TNF, and/or IFN-. Interestingly, IL-1 selectively
induces Fas expression on  cells but not on other isletsuggest that short-term local inflammation promotes
generation and activation of regulatory T cells, whereas cells. Accordingly, 90% of the  cells but few  cells of
pancreatic tissue from acutely diabetic patients expressprolonged inflammation somehow allows autoreactive
CD8 T cells to overcome these regulatory events. Fas (Moriwaki et al., 1999). Fas and its ligand, when
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Table 1. Strategies to Further Investigate the Role for CD8 T Cells in Human Autoimmune Diseases
Tools Objectives
Strategies to Identify Potential Target Self-Peptides
Reverse immunology approach (in vitro proteasome Identify naturally processed immunogenic self-peptides
digestion of candidate autoantigens, mass
spectrometry-sequencing analysis of the generated Evaluate the pathogenic potential of CD8 T cells recognizing
peptides, sensitization of target cells with the digests) “human” MHC:self-peptide complexes
HLA class I transgenic mouse models
Strategies to Characterize the Antigen Specificity and Function of Disease-Relevant CD8 T Cells
Expansion/cloning of tissue-infiltrating CD8 T cells. Further Investigate the antigen specificity of disease-relevant CD8 T cells
characterization using candidate antigens, synthetic Perform functional studies
peptide libraries, or target tissue/cell cDNA expression
libraries
Microdissection of target tissue (laser capture dissection) Analyze TCR (and ?) rearrangement of infiltrating CD8 T cells at
the single-cell level
Generate tools to monitor the antigen specificity of locally expanded
CD8 T cells
Strategies to Characterize Autoreactive CD8 T Cells
HLA class I:self-peptide multimers Isolate and study autoreactive CD8 T cells
Assess the frequency and the phenotype of autoreactive CD8 T
cells
Determine their presence and accumulation in affected tissues
Evaluate the affinity of self-reactive TCR
Molecular analysis at the single-cell level (ELISPOT, FACS Analyze the functional properties of individual autoreactive CD8 T
analysis, RT-PCR) cells
Characterization of TCR usage by autoreactive CD8 T cells Generate clonotypic probes for autoreactive CD8 T cells
(sorting of tetramer or cytokine T cells and evaluation Track autoreactive CD8 T cells ex vivo/in situ
of TCR usage by quantitative PCR, Immunoscope, and
sequencing)
simultaneously expressed on thyroid follicular cells, neurons, display greater susceptibility to Fas- than to
perforin-mediated lysis (Medana et al., 2000). Therefore,have also been proposed to play a detrimental role in
Hashimoto’s thyroiditis. Thus, the Fas-FasL interaction cytotoxicity may be involved at different stages of an
autoimmune process via different mechanisms (Fig-has the potential to kill target cells as innocent bystand-
ers, a mechanism used by autoreactive CD4 T cells to ure 1).
Activated CD8 T cells can produce very high levelskill  cells. Although CD8 T cells can use Fas-dependent
lysis to damage  cells, whether CD8 T cells can also of TNF and IFN-, which may contribute directly and/
or indirectly to target cell destruction in autoimmunekill target cells as bystanders or whether Fas-dependent
lysis by CD8 T cells requires a cognate interaction has diseases (Figure 1). When expressed in the islets of
prediabetic NOD mice, TNF enhances the presentationyet to be formally demonstrated.
The molecular nature of the recognized autoantigens of  cell self-antigens to diabetogenic CD8 T cells by
triggering TNFR on APCs (Green et al., 2000) and, possi-may influence the choice of the cytotoxicity pathway
that is employed by CD8 T cells in a given autoimmune bly, islet cells (Pakala et al., 1999).  cells express low
levels of TNFR1 constitutively, but express both TNFR1disorder. The avidity of the T cells involved at different
stages of disease may be another contributing factor, and TNFR2 during inflammation. TNF also plays an
effector role in inflammatory bowel disease (IBD) andsince Fas-mediated cytotoxicity may be elicited at a
lower threshold of avidity (of target cell-CTL interac- RA, although its cellular source is by no means restricted
to CD8 T cells. Mice expressing elevated levels of TNFtions) than perforin-mediated cytotoxicity. Alternatively,
 cells may change their susceptibility to Fas- versus develop arthritis and IBD. Furthermore, TNFR2-Ig fusion
proteins or humanized anti-TNF mAbs can ameliorateperforin-mediated cytotoxicity as the disease pro-
gresses, such as by undergoing changes in their ability IBD and RA patients. In addition, TNF can damage the
myelin sheath and can induce oligodendrocyte apopto-to bind and/or internalize perforin or granzyme B (Mo-
tyka et al., 2000) or in their ability to activate effector sis, suggesting an effector role for TNF-TNFR1 interac-
tions in the pathogenesis of EAE and MS. This view,caspases via different signaling cascades. It is possible
that diabetogenesis in NOD mice is initiated by CD8 and however, is at odds with observations suggesting that
TNF plays an anti-inflammatory role in EAE and thatCD4 clones capable of lysing  cells exclusively via Fas
and later amplified by clones that can kill via other death MS activity is exacerbated in patients receiving TNF-
blocking therapy. TNF family members are also powerfuleffector pathways, including perforin. Fas-FasL interac-
tions also appear to play a critical role in the induction paracrine inducers of other cytotoxic cytokines, such
as IL-1and IL-1, resulting in increased NO production.and progression of EAE but not in its effector phase
(Suvannavejh et al., 2000). Certain cell types, such as NO is directly responsible for inducing necrosis of 
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cells in response to IL-1 or to combinations of TNF, other alternative (Xu et al., 2001). These multimers target
specific CD8 T cells for apoptosis without eliciting CTLIFN-, and IL-1 but is not required for cytokine-induced
 cell apoptosis. Thus, TNF-TNFR interactions can also activity. Whether these strategies are useful in vivo re-
mains to be determined. The route of administration isindirectly lead to necrosis.
Much interest has centered on the role of IFN- in clearly another important consideration, as oral toler-
ance with MHC class I binding self-peptides has little,T1D. The importance of this cytokine depends on the
model and the stage of diabetes. IFN- is likely to have if any, beneficial effect in CD8-mediated models of T1D.
In many instances, however, the antigen specificitya number of pathogenic effects, including the upregula-
tion of MHC class I on the islets and facilitating the of the pathogenic CD8 T cells is not known or the disease
has already progressed to a stage where antigen-spe-homing of CD8 T cells to the islets. Although IFN-R
knockout mice do not develop diabetes, both IFN- and cific therapy may be inefficient. Early treatment with
depleting anti-CD8 mAbs or other molecules inhibitingIFN-R knockout mice do so with only slightly deceler-
ated kinetics, suggesting that IFN- is dispensable. This CD8 T cell activation or tissue transmigration might hold
promise. In this regard, a potential mechanism to blockcontrasts with the LCMV model of diabetes where IFN-
appears to play a crucial role, probably together with CD8 T cell-mediated disease is to interfere with costimu-
lation or T-helper-assisted differentiation of naive CD8other cytokines (Seewaldt et al., 2000).
T cells into effectors (Figure 1). Although direct blockade
of the CD28-CD80/CD86 costimulatory pathway by solu-Future Therapeutic Prospects
ble CTLA-4 may be effective in some instances, theseThe mechanisms leading to tissue destruction obviously
strategies carry the risk of abrogating the natural immu-depend on the particular disease but may also vary
nosuppressive action of regulatory T cells (Salomon etbetween patients with a given autoimmune disease. A
al., 2000). These CD4CD25 regulatory T cells have themajor task is to precisely define which immunological
potential to control CD8 T cell activation in vitro and inpathways are elicited in a given patient and to establish
vivo (Green et al., 2002). Clearly, a more precise under-general patterns. Easy access to tools allowing the
standing of the mechanisms underlying the collabora-quantification, sorting, and analysis of antigen-specific
tion between CD4 and CD8 T cells as well as the regula-CD8 T cells should help identify immunodominant self-
tion of autoreactive CD8 T cell activation in autoimmunepeptides and determine whether they are shared by
diseases is required to fully understand the implicationspatients bearing the same MHC class I alleles (Table
of these different therapeutic strategies.1). If so, a number of approaches might be applied to
Blockade of inflammatory cell recruitment and neu-promote antigen-specific tolerance (Figure 1). Some of
tralization of pathways used by CD8 T cells (and bythese approaches, such as systemic administration of
other immune cell types) to effect tissue damage couldagonist peptides or soluble MHC-peptide complexes,
also be used (Figure 1). Perhaps the best example of a Thave been validated in animal models of autoimmune
cell cytokine whose blockade has had clear therapeuticdiseases and result in deletion or anergy of autoreactive
benefit in some, but not all, autoimmune inflammation isCD8 T cells. The short half-life of peptides in circulation
TNF. Another non-antigen-specific strategy to interfereand the need for repeated administrations are but some
with CD8 T cell-mediated disease would be to inhibitof the limitations of peptide therapy in chronic autoim-
their recruitment to the target tissue, such as by blockingmune disorders. Another problem is the choice of both
molecules involved in chemoattraction, rolling, adhesionthe type and the dose of peptide. It is generally assumed
to postcapillary endothelium, and transmigration.that the peptide affinity for MHC is the primary determi-
While a considerable amount of information has beennant of the tolerogenic activity, such that high affinity for
obtained with respect to the role of CD8 T cells in experi-MHC and high doses are preferred over low affinity and
mental autoimmune diseases, much work remains to below doses. Studies employing high and low affinity mim-
done to define if pathogenesis of the human diseaseics of NRP in NOD mice have shown that the affinity of
equivalents occurs in a similar manner. Combinationthe MHC:peptide complex for T cells is another critical
therapy or approaches aiming at targeting both autore-variable, particularly under circumstances where the tar-
active CD4 and CD8 T cells will, in all likelihood, be moreget population comprises both high- and low-avidity T
efficacious than sharply focused strategies. Investigat-cells. For example, high doses of low-affinity ligands or
ing therapeutic options in the experimental models willlow doses of high-affinity ligands are effective, but low
hopefully ultimately provide new directions for treatmentdoses of low-affinity ligands accelerate disease by acti-
of many of these diseases, which are increasing in fre-vating high-avidity T cells. This is akin to the activation
quency.of MBP-reactive CD4 T cells and disease exacerbation
in some MS patients treated with a mutant MBP peptide
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